Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited

Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments Delivers near-term revenue and profitability with 2025 normalized revenue of US$82,232,000 (approximately RMB566,299,000) with an EBITDA of US$27,273,000 (approximately RMB187,818,000). Strong synergies with Everest’s existing portfolio and enhances […]